Key result
Early post-TAVR leaflet thrombosis occurs in >15% of patients, presenting a treatable target for adverse events.
Why the study?
Long-term outcomes after TAVR, including thromboembolic risk and valve deterioration related to leaflet thrombosis, remain uncertain.
Highlights a common, potentially modifiable post-TAVR risk factor; leaves open optimal management pending prospective trials.
Transcatheter aortic-valve replacement (TAVR) has transformed the treatment of severe aortic stenosis. However, questions remain regarding the long-term outcomes of this procedure, including the risk of thromboembolic complications and valve deterioration. It has been recognized that leaflet thrombosis of surgically implanted bioprosthetic valves may result in stenosis and could be reversed by oral anticoagulants.1 With TAVR, early leaflet thrombosis has been identified by hypoattenuated leaflet thickening and reduced leaflet motion on four-dimensional computed tomographic (CT) imaging in more than 15% of patients and could be a potentially treatable contributor to future adverse events.2,3 Although the long-term effects of hypoattenuated leaflet . . .
No takes yet. Share an insight, caveat, or question.
Nishimura et al. (2020) conducted an editorial in Severe aortic stenosis. Transcatheter aortic-valve replacement (TAVR) was evaluated. Early leaflet thrombosis after transcatheter aortic-valve replacement is identified in more than 15% of patients and represents a potentially treatable contributor to future adverse events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: